ArticleCureus2025
Safety and Efficacy of Latitud™ Hip Replacement in Total Hip Arthroplasty: An Observational Study in Kazakhstan.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTotal hip replacement (THR) is one of the most successful surgical procedures globally for managing end-stage hip osteoarthritis. Latitud™ (Meril Healthcare Pvt. Ltd., Gujarat, India) hip replacement system is at the forefront of restoring mobility and improving patient outcomes. This study aimed to evaluate the safety and effectiveness of the Latitud™ hip replacement in total hip arthroplasty.
methodsIn this retrospective, single-center, post-market, observational study, patients who underwent THR and were treated in our hospital from 2018 to 2020 were included. The primary outcome was the THR-related intra- and postoperative complications and revision rate at one-year follow-up. Secondary outcomes were other patient-reported outcomes, radiographic analysis, Harris hip score, adverse events, implant dislocation, and implant survivorship rate. Data were collected using a pre-designed data collection form.
resultsA total of 150 patients with a mean age of 53.90 ± 11.44 years were enrolled. The surgical procedures were successful without any major complications. There was a significant (p < 0.001) improvement in the Harris hip score. No death was observed throughout the study. There was one (0.67%) intra-operative fracture, with the patient having a closed comminuted fracture of the upper and middle third of the left femur and anemia. Seven patients (4.67%) required postoperative blood transfusions. During the follow-up period, there was no revision surgery or implant dislocation.
conclusionThis observational study suggests that the Latitud™ hip replacement system was favorable in terms of safety and effective in a real-world setting in Kazakhstan. The study showed promising results in pain alleviation, functional improvement, and implant survivorship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.